ACA
EVLO

Affinity Capital Advisors’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Affinity Capital Advisors’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-530
Closed -$1.92K – 140
2023
Q1 		$1.92K Buy
+530
New +$8.18K ﹤0.01% 124

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Affinity Capital Advisors's EVLO Position: Q2 2023 in Review

Affinity Capital Advisors sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2023, closing a stake of 530 shares — an estimated $1.92K sold.

Affinity Capital Advisors first reported a position in EVLO in Q1 2023 and held it in 1 quarter. The position peaked at $1.92K in Q1 2023. 25 funds tracked by Wall St. Rank hold EVLO as of Q2 2023.

  • Affinity Capital Advisors reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Affinity Capital Advisors sold 530 Evelo Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.92K.
  • Affinity Capital Advisors first reported a position in Evelo Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Affinity Capital Advisors's Evelo Biosciences, Inc. Common Stock position peaked at $1.92K in Q1 2023.
  • 25 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2023.

Based on Affinity Capital Advisors's 13F filing for Q2 2023, filed 14 Jul 2023.